Company intelligence / Profile preview

Alliance Discovery

Doylestown, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Alliance Discovery is a pre-clinical stage biotechnology company based at the Pennsylvania Biotechnology Center in Doylestown, Pennsylvania. The company focuses on the design, synthesis, and development of novel small-molecule therapeutics targeting chemokine receptors to prevent and treat cancer metastasis. Its lead program centers on CX3CR1 antagonists, including the potent and selective small-molecule inhibitors JMS-17-2 and JMS-FX-68, which have demonstrated efficacy in impairing the seeding and colonization of circulating tumor cells in preclinical models of breast, prostate, and pancreatic cancers.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Drexel University College of MedicineThe Wistar Institute

Beyond the preview

Go deeper on Alliance Discovery.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alliance Discovery.

Explore the full profile